ProHeart 12 is the only once-a-year heartworm preventive for dogs — a single injection of moxidectin, given at the clinic, that protects for twelve months. For owners who have watched a dog spit out a monthly chew or who travel and miss doses, that convenience is the whole point. But because it is an injectable, sustained-release product with a complicated safety history, the side-effect conversation is sharper than it is for a monthly pill.

This article is specifically about side effects, adverse-event reporting, and the owner-veterinarian conversation around an injectable moxidectin product. For how ProHeart 12 works, how it compares to ProHeart 6, dosing, and fit, see the ProHeart 6 vs ProHeart 12 comparison. For heartworm preventive failures and resistance, see our reported heartworm preventive failures analysis.

Quick answer

Most reactions to ProHeart 12 are mild and short-lived — vomiting, diarrhea, lethargy, and reduced appetite that resolve on their own. The reactions that worry veterinarians are allergic (anaphylaxis, facial swelling, hives) and, more rarely, neurologic (seizures, ataxia, trembling). Published work on the older six-month injectable found that more than 95% of allergic reactions occurred within the first three days after injection, which is why the watch period matters most right after the shot. Serious reactions are uncommon, and adverse-event reports filed after a product reaches the market do not, on their own, prove the product caused them.

What the FDA field study found

The effectiveness and safety data behind ProHeart 12 come from a well-controlled field study of 593 dogs (297 given ProHeart 12, 296 given a monthly oral preventive as an active control), observed over a 605-day period across two injections. The most common adverse reactions, and how they compared to the control group:

Two points from those numbers matter. First, the rates of vomiting and diarrhea were essentially the same as in dogs taking a monthly oral preventive — these are common, background-level signs in any group of dogs. Second, the serious signals (seizures, anaphylactoid reactions) were rare and only slightly above the control rate. One dog in the study had a severe seizure 19 days after the first injection and needed treatment; other seizures were mild, single events with no clear tie to the injection. Two dogs had mild-to-moderate hypersensitivity reactions within the first 24 hours, both recovered fully, and neither reacted to a second dose a year later.

What the label warns about

The ProHeart 12 label (NADA 141-519) lists the full post-marketing experience by body system. The ones owners should recognize:

• Immune: anaphylaxis and anaphylactoid reactions, hives (urticaria), head and facial swelling, itching, pale gums, collapse, cardiovascular shock, and, rarely, immune-mediated destruction of red blood cells or platelets (IMHA, IMTP).
• Neurologic: seizures, ataxia (incoordination), trembling, and hind-limb weakness.
• Gastrointestinal: vomiting and diarrhea, with or without blood, and drooling.
• Dermatologic: itching or swelling at the injection site.
• General: depression, lethargy, anorexia, fever, weight loss, weakness.

The label also carries specific cautions: do not give ProHeart 12 to dogs younger than 12 months, to sick, frail, or underweight dogs, or to dogs not first confirmed heartworm-negative. It warns to use caution in dogs with pre-existing allergic disease (food allergy, atopy, flea-allergy dermatitis) and notes that adverse reactions, including anaphylaxis, have been reported when moxidectin microspheres are given at the same visit as vaccines.

What adverse-event reports can and cannot tell you

Pet owners who read about ProHeart online are usually looking at two very different kinds of numbers. The field study above is controlled: every dog was watched, and reactions were counted systematically. Post-marketing adverse-event reports are the opposite — they are passive, voluntary, and uncontrolled.

An analysis of the FDA's public animal adverse-event reports — the same FDA Center for Veterinary Medicine openFDA database behind our broader adverse-event reporting analyses (analysis run date 2026-06-09) — shows how those reports look for moxidectin, the active ingredient in ProHeart 6 and ProHeart 12 and also used in topical products such as Advantage Multi. Moxidectin accounts for roughly 74,000 reports across all moxidectin products and species in the database, making it one of the most-reported parasiticide ingredients. Within those reports, the most common reaction terms are vomiting, diarrhea, lethargy, anorexia, and pruritus — but also anaphylaxis, facial swelling, hives, seizures, and ataxia, and roughly 3,800 list a fatal outcome.

Three caveats are essential before reading any meaning into those counts:

1. Reports are not proof of causation. The FDA collects them precisely so it can detect signals, but a report filed after a dog received a product does not mean the product caused the event.
2. The brand field is masked in the public data, so the moxidectin reports include all moxidectin products, not ProHeart 12 alone.
3. Voluntary reporting undercounts. A 2023 JAVMA analysis of the six-month injectable estimated roughly 3.9 adverse events per 10,000 doses sold between 2008 and 2016 — but emphasized that passive reporting means real rates are likely higher and that familiar products get reported less often over time.

The moxidectin report record also shows two clusters worth knowing about as context, not as evidence: a sharp concentration of reports in 2002–2004, the period around the original ProHeart 6 launch and its 2004 voluntary market withdrawal after reports of death, anaphylaxis, seizures, and blood and liver problems; and a steady rise from 2019 forward as ProHeart 12 reached the U.S. market. Higher report counts around a known safety event, or around a product launch when clinics are still learning a drug, reflect reporting intensity as much as true incidence.

Reaction timing: when to watch closest

Timing is the most actionable thing an owner takes away from the safety data. The same JAVMA analysis found that more than 95% of allergic reactions associated with the moxidectin injectable occurred within the first three days after exposure. The field study's two hypersensitivity reactions appeared within the first 24 hours. The ProHeart 12 Client Information Sheet is more specific still: it tells owners that most reactions occur within the first 24 hours and that severe allergic reactions may occur in the first two hours after the injection. Practical translation: the hours and days that matter most are right after the shot.

Watch for difficulty breathing, facial swelling, hives, pale gums, collapse, repeated vomiting or diarrhea, tremors, or seizures in that window. Anaphylaxis can come on within minutes to hours and is a veterinary emergency — call ahead or head to an emergency clinic rather than waiting.

Who is at higher risk

Risk is not uniform. The label, the field study, and the JAVMA analysis point to the same higher-risk groups:

• Dogs under 12 months are excluded from ProHeart 12 entirely.
• Sick, frail, or underweight dogs, and dogs that lose significant weight while on the product, are flagged as more likely to have a severe reaction.
• Dogs with pre-existing allergic disease — food allergy, atopy, flea-allergy dermatitis — should be approached with caution.
• Younger dogs and certain breeds showed higher odds of a rare adverse event in the 2023 JAVMA review.
• Dogs receiving vaccines at the same visit, because of the reported anaphylaxis signal with concurrent use.
• Dogs that are heartworm-positive, or with significant liver or kidney disease.

"Lack of efficacy" reports are a different question

One term that shows up prominently in moxidectin adverse-event data is not a side effect at all: "lack of efficacy — heartworm." These are reports in which a dog on a moxidectin preventive nonetheless tested positive for heartworm. That is a product-performance and heartworm-resistance question, not a safety one, and it overlaps with the broader heartworm preventive failures conversation. It is worth being aware that owners sometimes encounter these reports under the ProHeart banner and conflate them with side effects; they are different issues with different causes.

What to ask your veterinarian before the injection

• Is my dog heartworm-negative on a current test, and is she healthy enough today (good weight, no active illness)?
• Does my dog have any allergic disease, and is she up for vaccines today — or should we separate the injection from shots?
• What signs should I watch for in the next one to three days, and when do I call the clinic versus an emergency hospital?
• What do I do if she has vomiting, swelling, or trouble breathing after we go home?
• If she reacted to a monthly oral preventive in the past, does that change the calculus here?

When to call your veterinarian or emergency clinic

Seek care immediately if your dog shows any of the following after a ProHeart injection:

• Difficulty breathing, wheezing, or collapse (possible anaphylaxis)
• Sudden facial swelling, hives, or widespread redness
• Pale gums or weakness
• Seizures, tremors, or marked incoordination
• Repeated or bloody vomiting or diarrhea
• Yellowing of the gums or eyes, or unexplained bruising and bleeding

Call ahead so the clinic knows the product, the lot, and the time of injection. Most dogs tolerate ProHeart 12 well, and the convenience of twelve-month coverage is real — but the small minority who react tend to do so early, which is exactly when an owner who knows what to watch for makes the difference.

Sources

• DailyMed. PROHEART 12 (moxidectin) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e856da36-f717-4645-8841-27460cf87d91
• U.S. FDA. Animal Drugs @ FDA — ProHeart 12 label. https://animaldrugsatfda.fda.gov/
• U.S. FDA. FDA Approves ProHeart 12 (moxidectin) for Prevention of Heartworm Disease in Dogs. https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-proheart-12-moxidectin-prevention-heartworm-disease-dogs
• Saito EK, Moore GE, Morrison J, Spofford N, Yang M. Younger dogs of specific breeds are more likely to experience a rare adverse event after administration of extended-release injectable moxidectin heartworm preventive. JAVMA 2023;261(11). https://avmajournals.avma.org/view/journals/javma/261/11/javma.23.04.0217.xml
• VCA Animal Hospitals. Moxidectin Injectable. https://vcahospitals.com/know-your-pet/moxidectin-injectable
• U.S. FDA. Center for Veterinary Medicine — how to report an animal drug adverse event. https://www.fda.gov/animal-veterinary/safety-health/report-animal-drug-or-device-problem